. 2019 Jan 22;40:135–150. doi: 10.1016/j.ebiom.2018.12.016

Table 3.

Tumorigenicity of CD133⁺ pancreatic cancer cells from mice treated with rhHMGB1 or a vehicle control.

Injected cells	Treatment	Number of mice with tumors/total injected mice (% of mice with tumors)
Injected cells	Treatment	TLR2⁺	TLR2⁻	TLR4⁺	TLR4⁻
1000	PBS	2/8(25)	2/8(25)	2/8(25)	2/8(25)
1000	rhHMGB1	4/8(50)	2/8(25)	2/8(25)	4/8(50)
		(P = .608)	(P = 1.000)	(P = 1.000)	(P = .608)
10,000	PBS	2/8(25)	3/8(37.5)	3/8(37.5)	2/8(25)
10,000	rhHMGB1	6/8(75)	2/8(25)	3/8(37.5)	6/8(75)
		(P = .132)	(P = 1.000)	(P = 1.000)	(P = .132)
100,000	PBS	3/8(37.5)	5/8(62.5)	4/8(50)	4/8(50)
100,000	rhHMGB1	6/8(75)	4/8(50)	3/8(37.5)	6/8(75)
		(P = .315)	(P = 1.000)	(P = 1.000)	(P = .608)